FIGURE 1.
Overview of important considerations in patients with sarcoidosis-associated pulmonary hypertension (SAPH) [22, 23, 25]. ERA: endothelin receptor antagonists; PAH: pulmonary arterial hypertension; PD5: phosphodiesterase type-5 inhibitor; PH: pulmonary hypertension; RHC: right heart catheterisation.